This page uses content from Wikipedia and is licensed under CC BY-SA.


Clinical data
Trade namesSundralen, Symcorad, Symcor
ATC code
Pharmacokinetic data
Elimination half-life2.3–5 hours[1]
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass215.70 g/mol g·mol−1
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Tiamenidine (BAN, USAN, INN, also known as thiamenidine, Hoe 440) is a imidazoline compound that shares many of the pharmacological properties of clonidine. It acts as a centrally-acting α1 and α2 adrenergic receptor antagonist (with IC50 4.85 μM and 0.0091 μM, respectively).[2] In hypertensive volunteers, like clonidine, it significantly increased sinus node recovery time and lowered cardiac output.[3] It was marketed (as tiamenidine hydrochloride) by Sanofi-Aventis[4] under the brand name Sundralen[5] for the management of essential hypertension.[6]


Tiamenidine synthesis:[7]

Reaction of thiourea 1 with methyl iodide gives the corresponding S-methyl analogue (2), followed by heating with ethylenediamine, completes the synthesis of tiamenidine (3).

See also


  1. ^ Eckert, HG; Baudner, S; Weimer, KE; Wissmann, H (1981). "Determination of Tiamenidine in Biological Specimens by Radioimmunoassay". Arzneimittel-Forschung. 31 (3): 419–24. PMID 7194666.
  2. ^ Timmermans, PB; de Jonge, A; Thoolen, MJ; Wilffert, B; Batink, H; van Zwieten, PA (April 1984). "Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists". Journal of Medicinal Chemistry. 27 (4): 495–503. doi:10.1021/jm00370a011. PMID 6142954.
  3. ^ Roden, DM; Nadeau, JH; Primm, RK (June 1988). "Electrophysiologic and Hemodynamic Effects of Chronic Oral Therapy With the Alpha 2-agonists Clonidine and Tiamenidine in Hypertensive Volunteers". Clinical Pharmacology and Therapeutics. 43 (6): 648–54. doi:10.1038/clpt.1988.90. PMID 2897889.
  4. ^ "Pharmaceutical and healthcare online databases. Tiamenidine Hydrochloride". Retrieved 30 November 2015.
  5. ^ Ganten, D; Mulrow, Patrick J., eds. (2013). Pharmacology of Antihypertensive Therapeutics (1st ed.). [S.l.]: Springer-Verlag Berlin Heidelberg. p. 880. ISBN 978-3-642-74211-8.
  6. ^ Zamboulis, C; Hossmann, V; Dollery, CT; Eckert, H (October 1979). "Tiamenidine, a Centrally Acting Antihypertensive Drug in Essential Hypertension [proceedings]". British Journal of Clinical Pharmacology. 8 (4): 390. doi:10.1111/j.1365-2125.1979.tb04737.x. PMID 508528.
  7. ^ Rippel, H.; Ruschig, H.; Linder, E.; Schorr, M.; 1973, U.S. Patent 3,758,476